Michael Bell is a Senior Director at Eli Lilly and Company, where they lead efforts in preclinical drug discovery and have over 30 years of experience in medicinal chemistry. Having served as a Principal Research Scientist at Eli Lilly from 1994 to 2022, Michael developed expertise in nuclear hormone receptors, enzymes, and GPCRs, while contributing to multiple patents and publications. Michael holds a BS in Chemistry from the University of Notre Dame and is currently pursuing further education in Organic Chemistry at Indiana University–Purdue University Indianapolis.
Location
Indianapolis, United States